A detailed history of Bell Investment Advisors, Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Bell Investment Advisors, Inc holds 534 shares of BMY stock, worth $31,436. This represents 0.0% of its overall portfolio holdings.

Number of Shares
534
Previous 545 2.02%
Holding current value
$31,436
Previous $22,000 22.73%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$39.66 - $51.75 $436 - $569
-11 Reduced 2.02%
534 $27,000
Q2 2024

Aug 07, 2024

SELL
$40.25 - $52.99 $39,928 - $52,566
-992 Reduced 64.54%
545 $22,000
Q1 2024

May 08, 2024

BUY
$47.98 - $54.4 $11,323 - $12,838
236 Added 18.14%
1,537 $83,000
Q4 2023

Feb 14, 2024

SELL
$48.48 - $57.85 $15,222 - $18,164
-314 Reduced 19.44%
1,301 $66,000
Q3 2023

Nov 08, 2023

BUY
$57.89 - $64.73 $21,071 - $23,561
364 Added 29.1%
1,615 $93,000
Q2 2023

Aug 09, 2023

BUY
$63.71 - $70.74 $13,633 - $15,138
214 Added 20.64%
1,251 $80,000
Q1 2023

May 10, 2023

BUY
$65.71 - $74.53 $1,182 - $1,341
18 Added 1.77%
1,037 $71,000
Q4 2022

Feb 08, 2023

BUY
$68.48 - $81.09 $11,093 - $13,136
162 Added 18.9%
1,019 $73,000
Q3 2022

Nov 09, 2022

SELL
$0.13 - $76.84 $47 - $27,816
-362 Reduced 29.7%
857 $61,000
Q2 2022

Aug 12, 2022

BUY
$72.62 - $79.98 $31,226 - $34,391
430 Added 54.5%
1,219 $94,000
Q4 2021

Feb 14, 2022

BUY
$53.63 - $62.52 $15,820 - $18,443
295 Added 59.72%
789 $49,000
Q3 2021

Nov 12, 2021

BUY
$59.17 - $69.31 $29,229 - $34,239
494 New
494 $29,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Bell Investment Advisors, Inc Portfolio

Follow Bell Investment Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bell Investment Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bell Investment Advisors, Inc with notifications on news.